First-in-human dose-escalation study of VCN-01, a selective oncolytic adenovirus with hyaluronidase activity in patients with advanced or metastatic cancer. (December 2016) - Hidalgo, M.; Gil, M.; Garcia-Carbonero, R.; Alvarez, R.; Laquente, B.; Moreno, R.; De Martino, A.; Alemany, R.; Capella, G.; Blasi, E.; Viaplana, I.; Cascallo, M.; et al.